This trial is conducted in Europe. The aim of the trial is to investigate the effect of food on the pharmacokinetics (the exposure of the trial drug in the body) of NNC0123-0000-0338 in a tablet formulation in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
45
Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
Novo Nordisk Investigational Site
Neuss, Germany
Area under the serum insulin 338 concentration-time curve
Time frame: From a 0-288 hours NNC0123-0000-0338 serum concentration-time-curve based on 41 sampling time points
Area under the serum insulin 338 concentration-time curve
Time frame: From 0 to 288 hours after a single dose (SD)
Maximum observed serum insulin 338 concentration
Time frame: From 0 to 288 hours after a single dose (SD)
Area under the plasma capric acid concentration-time curve
Time frame: From 0 to 24 hours after a single dose
Maximum observed plasma capric acid concentration
Time frame: From 0 to 24 hours after a single dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.